ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $122 | -42.7% | 22,947 | +2.8% | 0.00% | – |
Q2 2023 | $213 | -2.3% | 22,325 | +13.0% | 0.00% | – |
Q1 2023 | $218 | -23.5% | 19,765 | +2.7% | 0.00% | – |
Q4 2022 | $285 | -100.0% | 19,246 | -89.3% | 0.00% | -100.0% |
Q3 2022 | $3,427,000 | -64.5% | 179,294 | -60.4% | 0.00% | 0.0% |
Q2 2022 | $9,655,000 | +11.7% | 453,057 | +1.0% | 0.00% | 0.0% |
Q1 2022 | $8,642,000 | -49.4% | 448,702 | -45.5% | 0.00% | -50.0% |
Q4 2021 | $17,073,000 | -12.2% | 823,168 | +1.2% | 0.00% | 0.0% |
Q3 2021 | $19,439,000 | -23.0% | 813,694 | -12.0% | 0.00% | 0.0% |
Q2 2021 | $25,242,000 | +32.9% | 924,958 | +40.9% | 0.00% | 0.0% |
Q1 2021 | $18,990,000 | +156.9% | 656,421 | +149.8% | 0.00% | +100.0% |
Q4 2020 | $7,392,000 | -74.5% | 262,781 | -73.5% | 0.00% | -66.7% |
Q3 2020 | $29,037,000 | -10.0% | 991,021 | -7.1% | 0.00% | -25.0% |
Q2 2020 | $32,252,000 | +10.4% | 1,066,540 | +8.8% | 0.00% | -20.0% |
Q1 2020 | $29,222,000 | – | 980,614 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
Two Seas Capital LP | 164,807 | $875,125 | 0.18% |